Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465359 · ClinicalTrials.gov registry record · NA
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A NA study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02465359 is a NA study of Chronic Inflammatory Demyelinating Polyneuropathy that has completed, run by University of South Florida. The registered enrollment target is 15 participants, below the 159-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02465359, a NA study of Chronic Inflammatory Demyelinating Polyneuropathy, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are using self administered subcutaneous immunoglobulin (SCIG) in patients with CIDP who require Intravenous immunoglobulin (IVIG). Safety, efficacy, and patient satisfaction will be examined.
Conditions Studied
Interventions
- DRUG Immune Globulin Subcutaneous (Human)
Study Locations (1)
Florida
- USF Dept of Neurology - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-09 |
| Est. Completion | 2021-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465359
The ClinicalTrials.gov registry entry for NCT02465359 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 159-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (91% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Immune Globulin Subcutaneous (Human) is the first listed.
NCT02465359 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02465359 about?
NCT02465359 is a clinical study titled "Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The investigators are using self administered subcutaneous immunoglobulin (SCIG) in patients with CIDP who require Intravenous immunoglobulin (IVIG). Safety, efficacy, and patient satisfaction will be examined.
What is the current status of trial NCT02465359?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2014-09. Estimated completion is 2021-05.
What conditions does trial NCT02465359 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT02465359?
The interventions under investigation include: Immune Globulin Subcutaneous (Human) (DRUG).
Who is sponsoring clinical trial NCT02465359?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02465359 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.